Ramm Pharma Corp.’s Acquisition Of 49% Interest in Canapar Corp.

Ramm Pharma investe in Canapar rilevandone il 49%

Cassels Brock & Blackwell and Grimaldi Studio Legale have represented Ramm Pharma in the transaction.

Ramm Pharma Corp., a leader in plant-derived cannabinoid (CBD) pharmaceutical and other cannabis-based products, completed its acquisition of a 49% interest Canapar Corp. from Canopy Rivers Corp.

Canapar is an Italy-based manufacturer and processor of CBD oil and isolates, which are increasingly used as an input into new commercial products in the health and wellness industries.

Canapar with its wholly owned subsidiaries in Europe is an Italy-based manufacturer and processor of CBD oil and isolates, which are increasingly used as an input into new commercial products in the health and wellness industries. 

RAMM is a leader in the field of cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other cannabis-based products.

The Cassels team deal team included Jay Goldman (Picture) and David Gardos (Securities and Cannabis) and Luke Woolford (M&A and Cannabis).

Grimaldi Studio Legale have represented Ramm Pharma in the transaction with a team including senior associate Matteo Trabacchin and associate Sara Marini for M&A matters;  partner Maurizio Mengassini for public law and regulatory aspects with junior associate Isabella Raso and Chiara Paganelli, and partner Sergio Massimiliano Sambri.

Involved fees earner: David Gardos – Cassels Brock & Blackwell LLP; Jay Goldman – Cassels Brock & Blackwell LLP; Luke Woolford – Cassels Brock & Blackwell LLP; Sara Marini – Grimaldi Studio Legale; Maurizio Mengassini – Grimaldi Studio Legale; Chiara Paganelli – Grimaldi Studio Legale; Isabella Raso – Grimaldi Studio Legale; Sergio Massimiliano Sambri – Grimaldi Studio Legale; Matteo Trabacchin – Grimaldi Studio Legale;

Law Firms: Cassels Brock & Blackwell LLP; Grimaldi Studio Legale;

Clients: Ramm Pharma Corp.;

Avatar

Author: Ambrogio Visconti